Over the last 18 months, the seemingly never-ending problems of the COVID-19 pandemic have put a strain on many people’s lives. Surgical procedures and doctor’s appointments have been rescheduled. However, the healthcare sector is progressively Improving, and more patients are visiting their doctors and scheduling elective surgeries. We’re also starting to witness technology improvements that have been delayed while the U.S. More clearances are granted by the Food and Drug Administration.
One recent approval, which came after several delays, could have a significant impact on how robotic surgery is performed in the future. On July 30, NuVasive got FDA approval for their Pulse platform, which had been a long time coming. Following a successful commercial debut, the product is now available for purchase in selected global markets, with further expansion planned for the rest of the year.
It’s a first of its type, according to the business, because it can be utilised in all spine surgeries and will be able to accommodate future applications like robotics and smart instruments. Pulse was supposed to be ready to roll out last year, according to NuVasive. FDA clearances were pushed back to this summer after a delay in February 2020 due to essential improvements revealed during beta testing, and a second delay in August 2020 due to COVID-19-related problems.COVID-19 hindered NuVasive’s timeline, but it also had a negative impact on revenue and earnings in 2020, with sales falling 10% year over year. Fortunately, in 2021, the corporation has recovered.